TIDMTRX
RNS Number : 7395X
Tissue Regenix Group PLC
27 April 2023
Tissue Regenix Group plc
('Tissue Regenix' or the 'Company')
Result of AGM, Share Reorganisation
&
Total Voting Rights
Tissue Regenix Group plc (AIM:TRX), the regenerative medical
device company, announces that at the Annual General Meeting
('AGM') held earlier today, all resolutions were duly passed on a
show of hands.
The results of the proxy votes received in respect of the
resolutions, given to the Chair prior to the meeting, are set out
below:
Resolution In favour % Against % Withheld
1 Ordinary 3,702,770,170 99.97 1,045,713 0.03 5,874,854
---------- --------------- ----------- ------ -----------
2 Ordinary 3,703,512,910 99.97 1,105,973 0.03 5,071,854
---------- --------------- ----------- ------ -----------
3 Ordinary 3,703,466,649 99.97 1,152,234 0.03 5,071,854
---------- --------------- ----------- ------ -----------
4 Ordinary 3,703,325,335 99.97 1,293,548 0.03 5,071,854
---------- --------------- ----------- ------ -----------
5 Ordinary 3,703,466,649 99.97 1,152,234 0.03 5,071,854
---------- --------------- ----------- ------ -----------
6 Ordinary 3,703,512,910 99.97 1,105,973 0.03 5,071,854
---------- --------------- ----------- ------ -----------
7 Ordinary 3,703,512,910 99.97 1,105,973 0.03 5,071,854
---------- --------------- ----------- ------ -----------
8 Ordinary 3,703,202,635 99.95 1,816,248 0.05 4,671,854
---------- --------------- ----------- ------ -----------
9 Ordinary 3,704,002,635 99.95 1,816,248 0.05 3,871,854
---------- --------------- ----------- ------ -----------
10 Ordinary 3,699,838,927 99.86 5,179,956 0.14 4,671,854
---------- --------------- ----------- ------ -----------
11 Ordinary 3,698,534,666 99.85 5,484,217 0.15 5,671,854
---------- --------------- ----------- ------ -----------
12 Ordinary 3,700,853,910 99.91 3,170,973 0.09 5,665,854
---------- --------------- ----------- ------ -----------
13 Special 3,702,744,910 99.96 1,548,973 0.04 5,396,854
---------- --------------- ----------- ------ -----------
14 Special 3,699,476,319 99.86 5,066,564 0.14 5,147,854
---------- --------------- ----------- ------ -----------
15 Special 3,703,206,896 99.95 1,811,987 0.05 4,671,854
---------- --------------- ----------- ------ -----------
Notes:
1. A "Vote withheld" is not counted in the calculation of the
percentage of shares voted "In favour" or "Against".
2. As at 26 April 2023, being the voting deadline date in
respect of the Annual General Meeting, the total number of Ordinary
Shares of 0.1p each in issue and the total number of voting rights
was 7,035,794,900 .
The full text of the resolutions passed at the AGM may be found
in the Notice of AGM published on 21 March 2023.
Share Reorganisation
10 Existing Ordinary Shares have been issued to ensure that as
part of the Share Reorganisation an exact whole number of
Consolidated Ordinary Shares are issued. At the Record Date, being
6 p.m. today, the 7,035,794,900 Existing Ordinary Shares will be
consolidated into 70,357,949 Consolidated Shares. Each Consolidated
Share will subsequently be subdivided into one New Ordinary Share
and one Class 2 Deferred Share. Immediately following the Share
Reorganisation, the Company's issued share capital will comprise
70,357,949 Ordinary Shares of 0.1p each
and 1,171,971,322 existing deferred shares and 70,357,949 Class 2 Deferred Shares.
Existing share certificates will cease to be valid following the
Share Reorganisation. New share certificates in respect of the New
Ordinary Shares will be issued by first class post at the risk of
the shareholder within 10 Business Days of each Admission. A CREST
Shareholder will have their CREST account credited with their New
Ordinary Shares following Admission.
Admission to trading on AIM and Total Voting Rights
Application has been made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM. It is
expected that Admission will become effective and that dealings in
the New Ordinary Shares will commence at 8.00 a.m. on 28 April
2023.
The New Ordinary Shares will trade under the ISIN: GB00BNTXR104
and SEDOL: BNTXR10.
Following Admission, the share capital of the Company will be
comprised of 70,357,949 New Ordinary Shares of which no shares are
held in treasury. Therefore, the total number of voting rights in
the Company is 70,357,949 . Shareholders may use this figure as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the FCA's Disclosure and
Transparency Rules.
This announcement should be read in conjunction with the Notice
of AGM that was published on 21 March 2023, copies of which are
available on the Company's website at www.tissueregenix.com and the
Company's announcement titled 'Proposed Share Reorganisation
Timetable' (the "Announcement"). Capitalised terms in this
announcement have the same meaning as given in the Announcement,
unless the context provides otherwise.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
Daniel Lee, Chief Executive Officer Via Walbrook PR
finnCap Ltd (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR & IR) Tel: +44(0)20 7933 8780
Alice Woodings/Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field
of regenerative medicine. The Company's patented decellularisation
technology ('dCELL(R)') removes DNA and other cellular material
from animal and human soft tissue, leaving an acellular tissue
scaffold that is not rejected by the patient's body and can then be
used to repair diseased or damaged body structures. Current
applications address many critical clinical needs in sports
medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specialises in regenerative
medicine and is dedicated to the development of high-quality,
innovative tissue scaffolds, which can enhance healing
opportunities in defects created by trauma and disease. CellRight's
human tissue products may be used in spine, trauma, general
orthopaedic, dental and ophthalmological surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGIRMBTMTJTBJJ
(END) Dow Jones Newswires
April 27, 2023 07:35 ET (11:35 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2023 to Apr 2024